WIXLIB

Norm Gitis, Ph.D.Paul M. GrandTom Kelly, M.Sc., MIE, Ph.D.Managing Partner, Lymo VenturesMedTech Committee,Life Science AngelsScreening Committee,Band of AngelsManaging Director,Pacific Coast OfficeRCT VenturesHead of DivisionIndustrial, Lifesciences & ConsumerEnterprise IrelandNorm Gitis obtained his Ph.D. inEngineering from the USSR Academy ofSciences in Moscow. Upon immigrationto the U.S., he was a visiting professor atMIT until IBM moved him to San Jose.Grand has more than twenty-fiveyears experience in venture capitaland the founding and management ofearly-stage companies in technologyand healthcare. He is responsible forsourcing RCT’s investments in medicaldevices and representing RCT on theboards of its portfolio companies. Since1990, Grand has built, operated, recruitedmanagement and raised financing foreight high technology, medical deviceand biotechnology companies.Tom Kelly is Head of Enterprise Ireland’sIndustrial, Lifesciences and ConsumerDivision. Enterprise Ireland is thegovernment body with the responsibilityfor the development of Ireland’sindigenous and natural resourcebased industries.Norm founded and ran two profitabletest-instrumentation companies, Centerfor Tribology, Inc. in Mountain View(1994–2000) and CETR in Campbell(2000–2011). He was twice named bythe Business Journal the CEO of Top20 Fastest Growing Private Companiesin Northern California. Upon successfulexit, Norm was VP of Bruker, a leadingmanufacturer of test instrumentation forlife sciences and other applications.Norm has authored over 150 scientificpapers, three books and over twodozen patents, chaired and organizedover three dozen international scientificconferences.Over the past three years, Norm hasbeen pursuing his passion of helpingmed-tech start-ups with funding, IP andbusiness development. His investmentportfolio includes twelve med-techstartup companies. Norm chairs a devicescreening committee of Life ScienceAngels and serves on a screeningcommittee of the Band of Angels, bothin Silicon Valley.Grand is actively involved in programs toencourage innovation and technologycommercialization and is a frequentspeaker, moderator and panelist athealthcare conferences. He serves asproducer and emcee for the MedTechInnovator accelerator and competition,which identifies and rewards outstandingearly-stage medical device companies.Grand is on the Oversight Committeesfor the Coulter Translational ResearchPartnership Programs at USC andUniversity of Washington. He haslectured, served as a reviewer for proofof concept and commercializationfocused funding programs, andmentored students and scientists atnumerous universities, including UCLA,Stanford, USC, UCSF, University ofUtah, the Keck Graduate Institute andUniversity of Colorado. Grand served asan investment advisor to the LARTA NIHCommercialization Assistance Programfor SBIR program awardees.He has responsibility for developingand implementing the organisations’strategies in Life Sciences, Engineering,and related sectors. He is recognisedas a “thought leader” on manufacturingand is a member of key government foralooking at the future of manufacturingin Ireland.He is based at Enterprise Ireland’soffices in East Point Plaza, Dublin 3, andis a member of its Executive Committee,and is Chairman of its Finance, JobExpansion and Capital InvestmentCommittees. He is also a member of theGoverning Body of Dublin Institute ofTechnology and a member of the Boardof NIBRT (The National Institute forBioprocessing Research and Training).Prior to taking up his current assignmenthe was senior manager within theScaling Division, leading a team ofspecialists in business developmentand innovation management, workingdirectly with a select group of fast growthclient firms.Earlier in his career he was Headof Enterprise Ireland’s TechnologyDevelopment Division, assisting firms toadopt best manufacturing and businesspractices and fostering innovationparticularly through new product andprocess R&D and technology transfer.4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 5

Emily Waldron LoughranJuan-Pablo MasJ. Casey McGlynnSenior Director of LicensingUCLA OIP-ISRPartnerAction Potential Venture CapitalPartnerWilson Sonsini Goodrich & RosatiEmily Loughran joined UCLA’s OIP-ISRin 1994 as a technology transfer officer.Currently, as the Senior Director ofLicensing, she manages the licensingand patent prosecution groups, andoversees the office’s large portfolioof invention disclosures, patents, andlicense agreements. Emily started inintellectual property administration at theCity of Hope Medical Center where shewas the Technology Transfer Managerresponsible for patenting and licensingactivities. Emily holds an MBA from USCand a BS from UC Berkeley.Juan-Pablo is a partner at ActionPotential Venture Capital in Palo Alto,CA, and invests in companies that arepioneering bioelectronic medicines andother enabling technologies. JuanPablo is on the Board of Directors ofSetPoint Medical. He was previouslyan investor at Lightstone Venturesand Morgenthaler Ventures, where hefocused on therapeutic medical devices,mobile health, and biopharmaceuticalinvestments. There he served as aBoard Observer at Ardian (acquired byMedtronic), Twelve (acquired Medtronic),Holaira, Miramar Labs, CabochonAesthetics (acquired by Ulthera/Merz),and SetPoint Medical.J. Casey McGlynn formed the LifeSciences Group at Wilson SonsiniGoodrich & Rosati in 1990. It isa nationally recognized practicerepresenting startups and emerginggrowth companies in the life sciencesfield—Medical Devices, Digital Health,Diagnostics and Biotechnology.Mr. McGlynn has formed, sold and takenpublic many of the most importantmedical device companies formedduring the last 30 years. Mr. McGlynnhas extensive hands-on experiencein helping entrepreneurs form, build,fund and sell their companies. Hehas close working relationships withan unparalleled list of entrepreneurs,doctors, investors, engineers andmanagers in the life sciences field.Prior to investing, Juan-Pablo led effortsin R&D and Strategy in Medtronic’sCardioVascular Division, includingPipeline Strategy, White-Spaceexpansion, Business Development,and M&A integration efforts. He wasnamed “Medtronic Inventor of The Year”in 2008, and has 30 patents, grantedor pending. Juan-Pablo also launchedEffient (prasugrel) during his tenure onthe Global Brand Strategy team at Eli Lilly& Co.Juan-Pablo earned an MBA fromStanford Graduate School of Business.He also conducted research in theNeurology Department at StanfordHospital, while completing an M.S.in Electrical Engineering at StanfordUniversity. There he worked onbiometric signal processing applicationssuch as neural-prosthetics, EMG-drivenfeedback systems, and improved ICDdetection algorithms.Juan-Pablo currently serves on theBoard of Directors of SetPoint Medical,and the Boston-based non-profit,InnerCity Weightlifting.6 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE

Jennifer McMahon, M.Sc.,B.Sc.AssociateSeroba Life SciencesJennifer McMahon joined the teamof Seroba Life Sciences in 2011. Shegraduated from University College,Dublin with an honours degree inPharmacology in 2010. Jennifer thenentered a Master’s degree programmein Biotechnology and Business to furtherher interest in the interface of biomedicalscience with commercialisation. Havingplaced first in her Master’s degreein 2011, Jennifer then joined SerobaLife Sciences’ Investment Team asan Investment Analyst. Jennifer is amember of and Dublin-hub Ambassadorof the Thousand Network (formerly theSandbox network), a global communityfor “exceptional innovators.” In October2015 Jennifer was recognised as oneof Ireland’s “Top 30 Under 30,” shapingthe future of business in the country.She guest-lectures on venture capitalat University College Dublin, TrinityCollege Dublin and the Royal Collegeof Surgeons, Ireland. Jennifer waspromoted to Senior Analyst in 2014.Seroba Life Sciences is a European lifesciences venture capital firm, focusedon investing in breakthrough healthcaretechnologies that promise to improvelives and make a difference worldwide.Headquartered in Ireland, they work withsome of Europe’s best entrepreneursdeveloping innovative medical devices,diagnostics and therapeutic drugs.Widya MulyasasmitaNew VenturesJohnson & Johnson InnovationWidya is part of the New Venturesteam at Johnson & Johnson CaliforniaInnovation Center, where shesupports deals and collaborationsacross consumer, medical device andpharmaceutical sectors.Widya comes to Johnson & Johnsonfrom McKinsey & Company, where shewas a management consultant advisingclients in healthcare and other industrieson corporate strategy, lean operations,and organizational health topics. Prior toMcKinsey, Widya worked at GE VenturesHealthcare and she also co-founded amedical device startup called Lap IQ,where she served as Chief Scientistdeveloping biodegradable woundclosure devices.Widya is a bioengineer with expertisein biomaterials, drug delivery, andregenerative medicine. She received herB.S. in Materials Science Engineeringand Bioengineering from the Universityof California Berkeley and her Ph.D. inBioengineering from Stanford Universitywhere she was a Siebel Scholar.Nader Pouratian, M.D.,Ph.D., FAANS, FACSAssociate ProfessorUCLA NeurosurgeryDr. Pouratian is an Associate Professor ofNeurosurgery and Radiation Oncologyand affiliated faculty in Bioengineeringand Neuroscience. He earned hisbachelors, medical, and Ph.D. degreesat UCLA before completing hisneurosurgical training and specialtytraining in functional neurosurgery atthe University of Virginia. He has broadyet in-depth training in both functionalneurosurgery and the acquisition andcomprehensive analysis of multiplebrain mapping modalities and haspublished extensively in the field ofhuman brain mapping, comparing humanbrain mapping signals from multiplemodalities, including functional MRI,optical imaging, evoked potentials,electrocortical stimulation mapping,electrocorticography, local fieldpotentials, and single unit recordings.As a neurosurgeon, neuroscientist,and bioengineer, he has the uniqueperspective and training to integratethese fields and take advantageof the unparalleled opportunitiespresented by neurosurgery to studyhuman brain function and designnovel neurotechnologies. His currentfocus is understanding the networkbasis of disease and designing novelnetwork-based interventions to addressneurological and psychiatric disease.4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 7

Kalyanam Shivkumar, M.D.,Ph.D., FHRS, FACCProfessor of Medicine, Radiology &BioengineeringDirector, UCLA Cardiac ArrhythmiaCenter & EP ProgramsDirector & Chief, InterventionalCardiovascular Programs, UCLAResearch Faculty, Molecular, Cellularand Integrative Physiology IDPDr. Shivkumar is a physician scientistwho serves as the director of theUCLA Cardiac Arrhythmia Center &EP Programs since its establishmentin 2002. His field of specialization isinterventional cardiac electrophysiology,and his research work relates tomechanisms of cardiac arrhythmias inhumans and the neurovisceral sciences.Dr. Shivkumar and his colleagues areactively involved in human mechanisticstudies, development of new intellectualproperty, and medical technology forcardiovascular therapeutics. He servesas a section editor of the society journal“Heart Rhythm,” associate editor of“Trends in Cardiovascular Medicine,”is on the editorial board of the journals“JACC,” “PACE,” “JACC-Clinical EP,” andis a peer reviewer for several basicscience and clinical journals and for theNIH in evaluating cardiac arrhythmia andneuroscience research. Dr. Shivkumarhas received several teaching awardsand has been nominated to serve theboard of examiners for Clinical CardiacElectrophysiology of the ABIM (AmericanBoard of Internal Medicine). He hasbeen elected to the membership of theAmerican Society of Clinical Investigation(ASCI) and serves as the institutionalrepresentative of UCLA for the ASCI.Dr. Shivkumar received his M.D. from theUniversity of Madras, India in 1991 andhis Ph.D. from UCLA in 2000.Lei (Eric) Tang, Ph.D., J.D.Managing PartnerTitanMed CapitalDr. Tang is the Managing Partner ofTitanMed Capital, an internationalhealthcare venture capital firm withoffices in Beijing, Hangzhou, andLos Angeles. The firm, together withits strategic partners, provides fundingand industry resources to emergingcompanies focused on medical devices,biotechnology, and healthcare services.Prior to co-founding TitanMed Capital,Dr. Tang co-founded ZD Medical, amedical device company focusing onproviding medical imaging as well asophthalmic solutions to addressingunmet healthcare needs. Dr. Tang holdsa Ph.D. degree in Biochemistry and CellBiology and J.D. degree, and workedfor many years as a patent attorney formajor law firms in the U.S. before cofounding ZD Medical.8 4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE

Startup Company ProfilesFounded in 2012 by UCLA physiciansand engineers, HyTek Medicaldeveloped the sOLVe Tube (SimplifiedOne Lung Ventilation for Everyone)to transform the space of One LungVentilation and satisfy an unmetneed. Packed with both evolutionaryand revolutionary innovations, thisnovel device solves ALL the clinicalshortcomings of the current doublelumen tubes without requiring newphysician training or increasing cost.HyTek Medical is poised to disrupt aspace dominated by multi-billion dollarcompanies.PneumoGel is a hydrogel productdeveloped at UCLA and delivered onthe surface of the lung during lungbiopsies to seal the needle tract.PneumoGel serves to limit the rate ofpneumothorax from lung biopsies, acommon and expensive complicationwhich can be seen in up to 40% ofpatients. Medicare data have showna 10-fold increase in the cost of lungbiopsy to 35K when complicated bypneumothorax. KASH Scientific Inc.has licensed PneumoGel, the deliverysystem and the process from UCLA, andis in the process of performing preclinicalanimal trial. PneumoGel is patented inthe U.S., Europe, China and India. KASHScientific is looking for strategic partnersin field to fund the animal trial and FDA510K clearance.Hypothermia Devices, Inc. (“HTD”)designs and manufactures digitallycontrolled and non-invasive cooling/heating devices for a wide range ofmedical applications, including devicesfor the treatment of patients who suffera cardiac arrest. HTD’s heat exchangesystem is a substantial improvementover current hypothermia devicesas it is the first to use thermoelectriccoolers as direct cooling agents tocreate hypothermia. Our devices arecapable of cooling and heating tissuevery quickly and with a level of precisionthat, until now, has been impossible toattain. Moreover, unlike current systems,HTD’s system is: (1) battery operated; (2)portable; (3) compact; and (4) lightweight.It can be used both by first respondersand in the hospital setting. Currentcooling devices use technology that hasexisted for decades to cool patients.HTD’s mission is to bring medical coolinginto the digital age.4TH ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE 9

UCLA Medical Device TechnologiesAvailable for Licensing10 UCLA MEDICAL DEVICE PARTNERING CONFERENCE

Neuromodulation andRecording TechnologiesA Highly-Efficient Near-FieldWireless Power Transfer Systemthat is Immune to Distance and/orCoupling-Coefficient VariationsPower transfer technologies transferpower optimally at one specific distance.As a result, product designs may requirea constant distance and therefore includethings like magnets in cochlear productsto align the implant and external earpiece.UCLA researchers from the Departmentof Electrical Engineering have developeda wireless power transfer system that candeliver stable power to the load over a largerange of distances. Additionally, the circuitryis mainly built at the power transmitter sideof the system, allowing the receiver end (e.g.biomedical implant) to remain very small.UCLA Case No. 2016-390LEAD INVENTOR: Asad AbidiPatent Status: PendingA High Dynamic-Range SensingFront-End for Neural SignalRecording SystemsThe ability for neuromodulation systems tosimultaneously stimulate and record deepbrain areas is currently only achievablein bulky wall-plugged systems that cancapture tiny signals in the presence of largestimulation artifacts. Implantable devicesare low power, but have inadequate inputsignal range. UCLA researchers from theDepartment of Electrical Engineering havedesigned a technology that achievessufficient signal range and power levelsthat are suitable for implants. This enablesconcurrent sensing and stimulation in naturalliving environment, thereby greatly improvingthe ability to provide timely and efficacioustherapeutic response.UCLA Case No. 2016-100LEAD INVENTOR: Dejan MarkovicPatent Status: PendingAutonomous ThermoelectricEnergy-Harvesting Platform forBiomedical SensorsTo make thermoelectric energy harvesters(TEH) a truly autonomous energy sourcefor size-constrained, wireless biomedicalsensors and eliminate the need for batteries,it has been necessary to drastically improvetheir energy density and conversionefficiency. UCLA researchers from theDepartment of Electrical Engineering havedeveloped an autonomous energy source forimplantable biosensors by developing a TEHthat can operate with a 68% end-to-end peakefficiency with 20ms tracking time, andstart-up voltages as low as 65mV. A 645µWregulated output power was harvested fromthe head of a rat (0.83cm2 surface area)with an implanted TEH device. The newTEH device achieves a 7.9x improvementin regulated power density and representsthe first fully autonomous energy harvestingplatform for energy-starved applications.UCLA Case No. 2015-245LEAD INVENTOR: Dejan MarkovicPatent Status: PendingMethod, Apparatus, and Circuit toMonitor Cardiac Disease, ControlArrhythmias and Function byModulating the Nervous SystemMost heart conditions are characterized bydetectable abnormalities of electrical (neural)heart function, but currently there existsvery limited technology for the prolongedactive monitoring and early stage treatmentof these abnormalities. Dr. KalyanamShivkumar’s technology is a neural recordingand analysis system for the diagnosis,continuous monitoring, and treatment ofheart disease. The system records heartneurons using electrodes implanted in oraround the heart wherein the electrodescan deliver neuro-modulatory stimulation tocorrect for functional abnormalities.UCLA Case No. 2015-093LEAD INVENTOR: Kalyanam ShivkumarPatent Status: PendingEVENT SPEAKERWireless Implantable System toRe

University of California, Los Angeles (UCLA) and Executive Director of the UCLA Business of Science Center. He serves as Co-Chairman of the Zhejiang California NanoSystems Institute in the People’s Republic of China (PRC) and is a Director of the first joint venture bank in the PRC, Xiam